Latest Webinar on Building a Protected PCI Program Features the University of Washington Heart Center in Seattle
The Building a Protected PCI Program series* presents a webinar entitled “The Programmatic Approach to Teaching, Tactics and Techniques” from the University of Washington (UW) Heart Center in Seattle, WA. The presenters are all members of the UW Heart Center and include Dr. William Lombardi, Director, Complex Coronary Artery Disease Therapies; Dr. James McCabe, Medical Director, Cardiac Catheterization Laboratories; Dr. Creighton Don, Interventional Cardiologist; Dr. Jason Smith, Cardiothoracic Surgeon; and Dr. Claudius Mahr, Medical Director of Advanced Heart Failure. Mary Tierney, Chief Content Officer for Cardiovascular Business introduces the topic—view the webinar below.
The UW Heart Center is an international training site for complex PCI, hemodynamic support with Impella, Protected PCI, atherectomy, and CTO-PCI. The UW Heart Center is dedicated to improving the skills of interventional cardiologists, and several avenues of training are discussed. One unique way was to open privileges to UW to any physician licensed in the state of WA—the patient and physician both come to UW, the patient remains with the physician, and is treated at UW. The physician learns new devices, new skills, and new techniques to bring back to their home institution.
To reach a broader audience, the UW Heart Center teaches through a combination of lectures and live broadcasts of real cases from the cardiac catheterization laboratory. This includes information on the skills needed for Protected PCI, the role of hemodynamic support, and placement of the Impella device. The UW Heart Center also provides advice for heart teams who want to optimize their approach or start a heart team program.
The UW heart team consists of interventional cardiologists, cardiac surgeons, and heart failure experts who work together to share their expertise and provide the best plan of care for each patient. UW Heart Center measures patient outcomes through quality of life surveys, depression scores, and evaluating the life limitations of patients. The benefits seen from this approach are both clinical—allowing physicians to conduct a complete revascularization procedure, which benefits patients, and economic—and financial, as costs are decreased due to reduced hospitalizations and fewer recurrent myocardial infarctions.
Watch this instructive webinar above to learn about training for Protected PCI, what to consider when building a Protected PCI program, and how to build acceptance for a Protected PCI program at your institution.
*The webinar was produced by Cardiovascular Business. It is the second part of the series entitled “Building a Protected PCI Program”.
Impella® Device — Indication & Safety Information
INDICATIONS FOR USE
The Impella 2.5® and Impella CP® Systems are temporary (≤ 6 hours) ventricular support devices indicated for use during high-risk percutaneous coronary interventions (PCI) performed in elective or urgent, hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is the appropriate therapeutic option. Use of the Impella 2.5 and Impella CP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri- and post-procedural adverse events.
The Impella 2.5®, Impella CP®, Impella 5.0®, and Impella LD® Catheters, in conjunction with the Automated Impella Controller (collectively, “Impella® System Therapy”), are temporary ventricular support devices intended for short term use (≤ 4 days for the Impella 2.5 and Impella CP, and ≤ 6 days for the Impella 5.0, and Impella LD) and indicated for the treatment of ongoing cardiogenic shock that occurs immediately (< 48 hours) following acute myocardial infarction or open heart surgery or in the setting of cardiomyopathy, including peripartum cardiomyopathy, or myocarditis as a result of isolated left ventricular failure that is not responsive to optimal medical management and conventional treatment measures (including volume loading and use of pressors and inotropes, with or without IABP). The intent of Impella System Therapy is to reduce ventricular work and to provide the circulatory support necessary to allow heart recovery and early assessment of residual myocardial function.
Important Risk Information for Impella devices
The Impella 2.5, Impella CP, Impella 5.0 and Impella LD are contraindicated for use with patients experiencing any of the following conditions: Mural thrombus in the left ventricle; Presence of a mechanical aortic valve or heart constrictive device; Aortic valve stenosis/calcification (equivalent to an orifice area of 0.6 cm2 or less); Moderate to severe aortic insufficiency (echocardiographic assessment graded as ≥ +2); Severe peripheral arterial disease precluding placement of the Impella System; Significant right heart failure*; Combined cardiorespiratory failure*; Presence of an Atrial or Ventricular Septal Defect (including post-infarct VSD)*; Left ventricular rupture*; Cardiac tamponade*
* This condition is a contraindication for the cardiogenic shock indication only.
POTENTIAL ADVERSE EVENTS
Acute renal dysfunction, Aortic valve injury, Bleeding, Cardiogenic shock, Cerebral vascular accident/Stroke, Death, Hemolysis, Limb ischemia, Myocardial infarction, Renal failure, Thrombocytopenia and Vascular injury
In addition to the risks above, there are other WARNINGS and PRECAUTIONS associated with Impella devices. Visit http://www.abiomed.com/important-safety-information to learn more.
Right-Side Support – Indication & Safety Info.
INDICATIONS FOR USE
The Impella RP® System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area ≥1.5 m2, who develop acute right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery.
Important Risk Information for Impella RP
The Impella RP System is contraindicated for patients with the following conditions: Disorders of the pulmonary artery wall that would preclude placement or correct positioning of the Impella RP device. Mechanical valves, severe valvular stenosis or valvular regurgitation of the tricuspid or pulmonary valve. Mural thrombus of the right atrium or vena cava. Anatomic conditions precluding insertion of the pump. Presence of a vena cava filter or caval interruption device, unless there is clear access from the femoral vein to the right atrium that is large enough to accommodate a 22 Fr catheter.
POTENTIAL ADVERSE EVENTS
The potential adverse effects (eg, complications) associated with the use of the Impella RP System: Arrhythmia, Atrial fibrillation, Bleeding, Cardiac tamponade, Cardiogenic shock, Death, Device malfunction, Hemolysis, Hepatic failure, Insertion site infection, Perforation, Phlegmasia cerulea dolens (a severe form of deep venous thrombosis), Pulmonary valve insufficiency, Respiratory dysfunction, Sepsis, Thrombocytopenia, Thrombotic vascular (non-central nervous system) complication, Tricuspid valve injury, Vascular injury, Venous thrombosis, Ventricular fibrillation and/or tachycardia.
In addition to the risks above, there are other WARNINGS and PRECAUTIONS associated with Impella RP®. Visit http://www.abiomed.com/impella/impella-rp to learn more.
General Indication and Safety Information
To learn more about the Impella platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: www.protectedpci.com/indications-use-safety-information/